These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Myelodysplastic syndromes: the pediatric point of view. Locatelli F; Zecca M; Pession A; Maserati E; De Stefano P; Severi F Haematologica; 1995; 80(3):268-79. PubMed ID: 7672722 [TBL] [Abstract][Full Text] [Related]
5. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Kao JM; McMillan A; Greenberg PL Am J Hematol; 2008 Oct; 83(10):765-70. PubMed ID: 18645988 [TBL] [Abstract][Full Text] [Related]
6. Cytogenetic characteristics of patients with signs and symptoms of myelodysplastic syndromes in the State of Pará, Brazil. Pinto GR; Overal DJ; Moraes LS; Van Den Berg AV; Lemos JA; Smith Mde A; Burbano RR Genet Mol Res; 2005 Mar; 4(1):18-30. PubMed ID: 15841432 [TBL] [Abstract][Full Text] [Related]
7. A comparative review of classification systems in myelodysplastic syndromes (MDS). Bennett JM Semin Oncol; 2005 Aug; 32(4 Suppl 5):S3-10. PubMed ID: 16085011 [TBL] [Abstract][Full Text] [Related]
8. Detection of risk groups in myelodysplastic syndromes. A multicenter study. Belli C; Acevedo S; Bengio R; Arrossagaray G; Watman N; Rossi N; García J; Flores G; Goldztein S; Larripa I Haematologica; 2002 Jan; 87(1):9-16. PubMed ID: 11801460 [TBL] [Abstract][Full Text] [Related]
9. Cytogenetic studies in 32 patients with myelodysplastic syndrome: insights to specific chromosomal abnormalities and prognosis. Taniwaki M; Horiike S; Inazawa J; Nishida K; Misawa S; Takino T; Abe T Jpn J Clin Oncol; 1987 Jun; 17(2):141-50. PubMed ID: 3613138 [TBL] [Abstract][Full Text] [Related]